These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36533099)

  • 21. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.
    Schoels MM; Aletaha D; Alasti F; Smolen JS
    Ann Rheum Dis; 2016 May; 75(5):811-8. PubMed ID: 26269398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland.
    Soini E; Asseburg C; Taiha M; Puolakka K; Purcaru O; Luosujärvi R
    Adv Ther; 2017 Oct; 34(10):2316-2332. PubMed ID: 28975568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire.
    Tillett W; Lin CY; Zbrozek A; Sprabery AT; Birt J
    Rheumatol Ther; 2019 Sep; 6(3):379-391. PubMed ID: 31154634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.
    van der Heijde D; Deodhar A; Fleischmann R; Mease PJ; Rudwaleit M; Nurminen T; Davies O
    Arthritis Care Res (Hoboken); 2017 Jul; 69(7):1030-1039. PubMed ID: 27696727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
    Feagan BG; Reilly MC; Gerlier L; Brabant Y; Brown M; Schreiber S
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1276-85. PubMed ID: 20298497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
    Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
    Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
    Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52.
    Behrens F; Leage SL; Sapin C; Baou CE; De La Torre I; Meszaros G; Schett G; Combe B; van den Bosch F; Gossec L
    Clin Rheumatol; 2021 Dec; 40(12):4943-4954. PubMed ID: 34515902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol.
    Lacroix BD; Karlsson MO; Friberg LE
    CPT Pharmacometrics Syst Pharmacol; 2014 Oct; 3(10):e143. PubMed ID: 25353186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.
    Mease P; Deodhar A; Fleischmann R; Wollenhaupt J; Gladman D; Leszczyński P; Vitek P; Turkiewicz A; Khraishi M; FitzGerald O; Landewé R; de Longueville M; Hoepken B; Peterson L; van der Heijde D
    RMD Open; 2015; 1(1):e000119. PubMed ID: 26509074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.
    Dhillon S
    Drugs; 2014 Jun; 74(9):999-1016. PubMed ID: 24919863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.
    Curtis JR; Herrem C; Ndlovu 'N; O'Brien C; Yazici Y
    Arthritis Res Ther; 2017 Sep; 19(1):215. PubMed ID: 28962590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V; Jobanputra P; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Kynaston-Pearson FJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD007649. PubMed ID: 25231904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.
    Mease PJ; Kavanaugh A; Ogdie A; Wells AF; Bergman M; Gladman DD; Richter S; Teng L; Jardon S; Smolen JS
    J Rheumatol; 2022 Jul; 49(7):694-699. PubMed ID: 35428720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA).
    Osterhaus JT; Purcaru O; Richard L
    Arthritis Res Ther; 2009; 11(3):R73. PubMed ID: 19457255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Certolizumab pegol: in rheumatoid arthritis.
    Duggan ST; Keam SJ
    BioDrugs; 2009; 23(6):407-17. PubMed ID: 19894782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
    van der Heijde D; Fleischmann R; Wollenhaupt J; Deodhar A; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; Mease PJ
    Ann Rheum Dis; 2014 Jan; 73(1):233-7. PubMed ID: 23942869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study.
    Karadag O; Dalkilic E; Ayan G; Kucuksahin O; Kasifoglu T; Yilmaz N; Koca SS; Yazisiz V; Erten PT; Sayarlioglu M; Terzioglu ME; Erten S; Kalyoncu U
    Clin Rheumatol; 2022 Jan; 41(1):85-94. PubMed ID: 34477993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V; Jobanputra P; Burls A; Cabello JB; Gálvez Muñoz JG; Saiz Cuenca ES; Fry-Smith A
    Cochrane Database Syst Rev; 2011 Feb; (2):CD007649. PubMed ID: 21328299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
    Nakagawa H; Tanaka Y; Sano S; Kameda H; Taniguchi A; Kashiwagi T; Kawaberi T; Kimura J; Morita A
    Adv Ther; 2019 Mar; 36(3):691-707. PubMed ID: 30661197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.